iRhythm agrees to buy VitalConnect for $287.5 million
IRTC•Deal terms and expected financial impact
iRhythm expects the deal to lift its revenue growth rate starting in 2027 while maintaining its 15% adjusted EBITDA margin target for 2027.
Closing is expected by the end of 2026. iRhythm will provide interim working capital financing starting with $10 million, up to $30 million.
iRhythm to expand into inpatient and hospital-to-home monitoring
iRhythm Technologies agreed to buy VitalConnect for about $287.5 million, expanding beyond ambulatory monitoring into inpatient and hospital-to-home settings.
Consideration includes about $237.5 million in cash from iRhythm’s balance sheet and about $50 million in iRhythm common stock.
VitalConnect adds mobile cardiac telemetry and continuous multi-vitals monitoring, broadening iRhythm’s cardiac monitoring platform.
